Hvordan har det seg at du har fått en slik mail? Kjenner ikke din historie med selskapet, så spør av interesse 
Nei, men det hjelper å ha en slik personer som CEO i salgsprosesser.
Han har jo en helt annen tyngde inn mot større selskaper.
Om det er viktig for deg, så kan du jo bare bla deg oppover i tråden.
Første som slo meg også. Han er også største aksjonær og kanskje utålmodig ang. tempoet?
Like stor tyngde som styremedlem og største aksjonær 
Litt dypere dykk:
Business Background of James E. Thomas
James E. Thomas is a seasoned business executive and investor based in New Canaan, Connecticut, known for his roles in both the venture capital and maritime industries. He co-founded a successful healthcare-focused venture capital firm and later transitioned into leading investments in the global shipping sector. Throughout his career, Thomas has held numerous leadership positions, including board roles at various companies and organizations. He holds a B.S. in Economics from the Wharton School at the University of Pennsylvania (clarus therapeutics, inc. - SEC.gov).
Venture Capital Leadership in Healthcare
In 2002, James E. Thomas co-founded Thomas, McNerney & Partners, a Stamford, Connecticut-based venture capital firm focused on the healthcare and life sciences sector (James Thomas - Director at Stamford Health | The Org). As a Managing Partner of this firm, Thomas helped raise and manage significant investment funds dedicated to biotechnology, pharmaceutical, medical device, and related health technology companies (James E Thomas Partner/Co-Founder, Thomas Mcnerney & Partners). Under Thomas’s leadership, Thomas, McNerney & Partners raised multiple funds (including a second fund of $375 million) and invested in dozens of companies across the life science industry (Thomas, McNerney closes $375m life science fund). The firm and its partners ultimately deployed over $600 million into a portfolio of approximately 48 companies, many of which achieved successful outcomes (e.g. IPOs or acquisitions) (Thomas, McNerney closes $375m life science fund).
During his tenure in venture capital, Thomas often took active roles in the companies his firm backed. For example, he joined the board of Clarus Therapeutics, Inc. – a specialty pharmaceutical company – in February 2004 as part of an early investment in the company (clarus therapeutics, inc. - SEC.gov). (Clarus Therapeutics later became publicly traded, with Thomas reported as a significant shareholder (James E Thomas Net Worth (2025) - GuruFocus).) Thomas’s involvement with Thomas, McNerney & Partners continued through the 2000s and early 2010s; by 2016, as the firm’s initial funds matured, it was reported that Thomas intended to depart the venture firm amid its decision not to raise a new fund (Med-tech VC firm Thomas, McNerney and Partners won’t raise a …). This marked a turning point as he began to shift his focus to other business ventures.
Board Memberships and Leadership Roles
Throughout his career, James E. Thomas has held numerous board memberships and leadership positions in both corporate and non-profit organizations, leveraging his industry expertise and investor background:
-
Clarus Therapeutics, Inc. – Board Director. Thomas served on the board of this men’s health pharmaceutical company from its early days in 2004 (clarus therapeutics, inc. - SEC.gov). His role as a director coincided with his firm’s investment in Clarus and his significant equity stake in the company.
-
CAS Medical Systems, Inc. – Board Director. Thomas sat on the board of CAS Medical, a publicly traded medical device company specializing in patient monitoring technology (clarus therapeutics, inc. - SEC.gov). This involvement was part of Thomas’s broader engagement in the medical devices sector through venture investments.
-
Galil Medical Ltd. – Board Director. He served on the board of Galil Medical, a private medical technology company known for its innovative cryotherapy systems for cancer treatment (clarus therapeutics, inc. - SEC.gov). Thomas’s venture firm invested in Galil, and he remained a board member through the company’s growth (Galil was later acquired by a larger medical company in 2016).
-
Wright Medical Group, Inc. – Independent Director. In 2004, Thomas was elected to the board of Wright Medical Group, a publicly traded orthopedic devices manufacturer, as an independent director (Wright Medical Group, Inc. - SEC.gov). This board appointment reflected his prominence in the medical technology investment community. (He later retired from Wright Medical’s board after a period of service, choosing not to stand for re-election as noted in a company proxy statement.)
-
Stamford Health, Inc. – Board Member and Chair. Thomas became deeply involved in this regional healthcare organization (the parent of Stamford Hospital). He has served on Stamford Health’s Board of Directors and currently holds the position of Chairman of the Board (Thomas Maritime). Stamford Health is a roughly $900 million health-care system, and Thomas’s leadership role there underscores his commitment to the healthcare industry beyond for-profit ventures.
-
Second Stage Theater – Board Member/Trustee. In addition to his corporate roles, James E. Thomas has also served on the board of Second Stage Theater Company, a prominent non-profit theater organization in New York City (clarus therapeutics, inc. - SEC.gov). This involvement highlights his engagement in philanthropic and cultural endeavors alongside his business activities.
These varied board and leadership roles illustrate Thomas’s broad influence across industries – from guiding startup ventures and public companies in life sciences to steering non-profit institutions in healthcare and the arts.
Transition to Maritime Industry Ventures
After a distinguished career in healthcare venture capital, James E. Thomas expanded into a very different industry: international shipping and maritime investments. Around the late 2010s, Thomas co-founded and became Managing Partner of Thomas Maritime, as well as Managing Director of Ithaca Marine, companies through which he invests in the global shipping sector (James Thomas - Director at Stamford Health | The Org) (John F. Imhof Jr. to Host Interview at 32nd Annual Marine Money Week | Events | Vedder Thinking | Vedder Price). In these roles, he has shifted focus to owning, operating, and investing in maritime assets and related technologies.
Thomas Maritime is an investment firm that targets established and emerging opportunities in the international maritime industry, with a focus on traditional shipping markets and the application of new technologies (such as big data and clean tech) in ocean transportation (Thomas Maritime). Under Thomas’s leadership, Thomas Maritime and Ithaca Marine have been active owners/investors in various shipping ventures, reflecting his ability to translate his investment acumen to a new industry (James Thomas, Chair - Stamford Health).
By 2019, James E. Thomas was recognized in the shipping finance community; for instance, he was featured as a speaker at Marine Money Week (one of the largest ship finance conferences), where he was introduced as the Managing Director of Ithaca Marine and interviewed about his role as a “real, live ‘shipping man’” (John F. Imhof Jr. to Host Interview at 32nd Annual Marine Money Week | Events | Vedder Thinking | Vedder Price). This public appearance signaled Thomas’s successful transition into the maritime sphere and his credibility among global shipping industry leaders.
Summary
James E. Thomas’s business background spans multiple industries and roles. In venture capital, he helped fuel the growth of numerous healthcare companies as co-founder of Thomas, McNerney & Partners. He has held leadership and board positions in companies ranging from biotech startups to medical device firms and healthcare organizations. In the latter part of his career, Thomas reinvented himself as a maritime investor, founding and leading companies that invest in shipping and ocean technology. His diverse professional ventures – combined with his board service in both corporate and non-profit sectors – demonstrate a dynamic career marked by leadership in finance, entrepreneurship, and industry-specific expertise, from health sciences to global shipping.
Sources:
- Bloomberg profile of James E. Thomas (James E Thomas Partner/Co-Founder, Thomas Mcnerney & Partners) (Thomas, McNerney closes $375m life science fund) (venture firm focus and investment scope)
- Stamford Health Board of Directors profile (Thomas Maritime) (James Thomas, Chair - Stamford Health) (current shipping ventures and health system leadership)
- SEC filings and press releases (Clarus Therapeutics board role (clarus therapeutics, inc. - SEC.gov); multiple board memberships in CAS Medical, Galil Medical, Second Stage Theater (clarus therapeutics, inc. - SEC.gov); Wright Medical board appointment (Wright Medical Group, Inc. - SEC.gov))
- Marine industry event announcement (Thomas as Managing Director of Ithaca Marine in 2019) (John F. Imhof Jr. to Host Interview at 32nd Annual Marine Money Week | Events | Vedder Thinking | Vedder Price).
Jeg har vært i kontakt med Oks.
Innholdet i dialogen skal jeg ikke gjengi ordrett, men inntrykket nå er at dette er ønskelig og planlagt fra flere parter ( inkludert OKS). Fundamentet er lagt for stor suksess, og oks er tydelig på at James, som har stor lidenskap for selskapet og teknologien, er rett mann til å ta dette videre.
For øvrig et poeng at OKS forblir sterkt engasjert på Dcs vegne
12 Likes
Og årsaken til direkte kontakt (uoppfordret) til deg er vel et ledd i å ha «narrativkontroll» på tolkningen i det største foraet som følger selskapet? Det er i så fall helt legitimt, ikke ment som kritikk eller negativt. Tvert i mot tenker jeg det viser at de følger med og innforstått med sammensetningen i aksjonærbasen.
7 Likes
Dette høres jo egentlig veldig greit ut. At det er enighet at en som James med hans erfaring tar over. Kan ikke være annet enn positivt, men jeg er spent på hvordan markedet mottar dette.
Håper OKS fortsetter i Desert.
Han fortsetter nok ikke nei. Og for meg høres James mer ut som en midlertidig løsning.
Dette var noe de så seg nødt til å gjøre kjapt og da stepper han inn fra egne rekker som eneste kandidat.
Absolutt ingenting tyder på at dette er gjort kjapt.
Det fremstår ekstremt planlagt over tid, og med Oks stødige hånd i prosessen.
Det tror jeg også, noen ganger blir 1+1=2.
James Thomas joined Desert Control in 2023. Thomas has over 30 years of experience in finance and investment across various sectors and domains. He began his career at Goldman Sachs in London and is now the majority owner of Ithaca Marine. He has also served on the boards of more than 20 companies that have conducted multiple initial public offerings, 9 repeated stock issuances, and numerous mergers and acquisitions. Through Woods End Interests LLC, Thomas was the largest participant in the Private Placement and holds an ownership stake of approximately 8.5% in the Company prior to the issuance of any Offer Shares.
Og hvor i all verden får du den påstanden fra? OKS har vært en trygg og stabil CEO som har bygd selskapet stein for stein. Hvorfor skulle de liksom se seg nødt til å “kjapt få han ut” ?
1 Like
Selskapet er i spill
Det er oppkjøpsrykter og spekulasjoner i så og alle tråder her
Hva tror du er grunnen?
Bør taes positivt. Har alltid fryktet at det ville poppe opp en melding en dag om at OKS kaster inn håndkleet. Alle har sine begrensinger og OKS har gitt alt og mer til 24/7 år etter år. Svarer aksjonærer med lange betraktninger til alle døgnets tider og antall reisedager er ikke få. Det man ser her virker velregissert, med Sivertsen som en delaktig part. Et selskap som rigger seg klar til å ta de neste store stegene. Det O’store spørsmålet er om vi får ta del i reisen eller om det blir oppkjøp mens vi alle står med kofferten i hånden.
9 Likes
Jo takk, men så ikke annet i de 518 innleggene enn at Hayen er flink til å kontakte OKS direkte og har bidratt med mye bra innsikt i denne tråden.
Hvordan er eksponeringen til OKS herfra?
1 Like
Umulig å vite, men jeg tror ikke dette har vært planlagt.